

---

---

## HOUSE CONCURRENT RESOLUTION

REQUESTING THE DEPARTMENT OF HEALTH TO CONVENE A THERAPEUTIC  
PSILOCYBIN WORKING GROUP TO EXAMINE THE MEDICINAL AND  
THERAPEUTIC EFFECTS OF PSILOCYBIN AND DEVELOP A LONG-TERM  
STRATEGIC PLAN TO ENSURE THE AVAILABILITY OF MEDICINAL  
PSILOCYBIN OR PSILOCYBIN-BASED PRODUCTS THAT ARE SAFE,  
ACCESSIBLE, AND AFFORDABLE FOR ELIGIBLE ADULT PATIENTS.

1           WHEREAS, mental health conditions are treated in various  
2 ways depending on the condition and can include medication,  
3 therapy, and psychosocial services; and  
4

5           WHEREAS, these treatments, while effective for certain  
6 conditions and patients, do not treat all mental health  
7 conditions; and  
8

9           WHEREAS, psilocybin is a naturally-occurring chemical  
10 compound found in certain species of mushrooms; and  
11

12           WHEREAS, psilocybin can activate serotonin receptors in the  
13 brain; and  
14

15           WHEREAS, studies conducted by nationally and  
16 internationally recognized medical institutions indicate that  
17 psilocybin has shown efficacy, tolerability, and safety in the  
18 treatment of a variety of mental health conditions, including  
19 addiction, depression, anxiety disorders, and end-of-life  
20 psychological distress; and  
21

22           WHEREAS, the United States Food and Drug Administration has  
23 determined that preliminary clinical evidence indicates that  
24 psilocybin may demonstrate substantial improvement over  
25 available therapies for treatment-resistant depression and has  
26 granted a breakthrough therapy designation for a treatment that  
27 uses psilocybin as a therapy for treatment-resistant depression;  
28 and



# H.C.R. NO. 174

1  
2 WHEREAS, Hawaii has a shortage of mental health  
3 professionals, and should actively consider novel, innovative,  
4 and safe solutions to treat its citizens; now, therefore,  
5

6 BE IT RESOLVED by the House of Representatives of the  
7 Thirty-first Legislature of the State of Hawaii, Regular Session  
8 of 2021, the Senate concurring, that the Department of Health is  
9 requested to convene a Therapeutic Psilocybin Working Group, to  
10 be placed in the Department of Health for administrative  
11 purposes; and  
12

13 BE IT FURTHER RESOLVED that the Therapeutic Psilocybin  
14 Working Group is requested to examine:  
15

- 16 (1) Federal, state, and local laws, regulations,  
17 administrative rules, and procedures regarding the  
18 therapeutic use of psilocybin;  
19
- 20 (2) Available medical, psychological, and scientific  
21 studies, research, and other information relating to  
22 the safety and efficacy of psilocybin in treating  
23 mental health conditions; and  
24
- 25 (3) Requirements, specifications, and guidelines for a  
26 medical professional to prescribe and provide  
27 psilocybin to patients in jurisdictions where  
28 psilocybin is used to treat mental health conditions;  
29 and  
30

31 BE IT FURTHER RESOLVED that the Therapeutic Psilocybin  
32 Working Group is requested to develop a long-term strategic plan  
33 to ensure the availability of therapeutic psilocybin or  
34 psilocybin-based products that are safe, accessible, and  
35 affordable for adults twenty-one years of age or older; and  
36

37 BE IT FURTHER RESOLVED that the following individuals, or  
38 their respective designees, are requested to serve as members of  
39 the Therapeutic Psilocybin Working Group:



- 1           (1) The Director of Health, who is requested to serve as  
2           chairperson of the working group;
- 3
- 4           (2) The Attorney General;
- 5
- 6           (3) The Dean of the John A. Burns School of Medicine at  
7           the University of Hawaii at Manoa;
- 8
- 9           (4) The chairpersons of the Senate and House of  
10           Representatives standing committees whose subject  
11           matter purview is primarily responsible for reviewing  
12           legislation relating to health and to the Judiciary;
- 13
- 14           (5) The chairperson of the Hawaii State Council on Mental  
15           Health;
- 16
- 17           (6) A physician duly licensed under chapter 453, Hawaii  
18           Revised Statutes, or advanced practice registered  
19           nurse with the authority to prescribe psychotropic  
20           medication and duly licensed under chapter 457, Hawaii  
21           Revised Statutes, to be invited by the chairperson of  
22           the working group; and
- 23
- 24           (7) A psychiatrist duly licensed under chapter 453, Hawaii  
25           Revised Statutes, to be invited by the chairperson of  
26           the working group; and
- 27

28           BE IT FURTHER RESOLVED that the chairperson of the  
29           Therapeutic Psilocybin Working Group may invite other interested  
30           parties with relevant experience to join the working group; and

31

32           BE IT FURTHER RESOLVED that the Therapeutic Psilocybin  
33           Working Group is requested to submit a preliminary report of its  
34           findings and recommendations to the Legislature no later than  
35           twenty days prior to the convening of the Regular Session of  
36           2022, and a final report of its findings and recommendations,  
37           including any proposed legislation, to the Legislature no later  
38           than twenty days prior to the convening of the Regular Session  
39           of 2023; and

40

41           BE IT FURTHER RESOLVED that the Therapeutic Psilocybin  
42           Working Group be dissolved on July 1, 2023; and



# H.C.R. NO. 174

1  
2  
3  
4  
5  
6  
7  
8

BE IT FURTHER RESOLVED that certified copies of this Concurrent Resolution be transmitted to the Director of Health, Attorney General, and Dean of the John A. Burns School of Medicine.

OFFERED BY:

A handwritten signature in black ink, appearing to be "J. G. ...", written over a horizontal line.

MAR 12 2021

